Mizuho initiated coverage of Kymera Therapeutics (KYMR) with an Outperform rating and $81 price target The company’s lead asset KT-621 is positioned to demonstrate potentially compelling signals of efficacy in atopic dermatitis, the analyst tells investors in a research note. Piper expects the Phase 1b readout in Q4. It projects $2.6B in risk-adjusted 2035 worldwide sales and positive data in Q4.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $80 from $60 at Citi
- Nurix Therapeutics price target lowered to $22 from $25 at Wells Fargo
- Kymera Therapeutics: Promising Advancements and Strategic Collaborations Drive Buy Rating
- Kymera Therapeutics participates in a conference call with JPMorgan
- Kymera Therapeutics price target raised to $63 from $53 at Oppenheimer